IDEKOS is a new biopharmaceutical company dedicated to the development of new products to address the lack of treatment options for autoimmune diseases, with a primary focus on Celiac Disease (CS). CS is an inflammatory disease of the small intestine triggered by the ingestion of glutens contained in wheat, barley or rye. Patients with CS display various degrees of inflammation and symptoms that range from abdominal discomfort and bloating to marked diahrrea, malabsorption, growth disturbances in children and neurological manifestations. About 1% of Americans are affected. There is no treatment today other than a life-long gluten free diet. Patients with CS are at risk of developing complications such as anemia, osteoporosis and malignancies. The mortality risk is also higher in CS patients.
At IDEKOS, we develop new products that target a key element in the pathogenesis of CS.
For more information, please contact Bruno Delagneau M.D, CEO and Founder.